754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)

754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)

Bibliographic Details
Main Authors: Haven Garber, Saranya Chumsri, Yazan Migdady, Chul Kim, Erika Hamilton, Jennifer Specht, Babar Bashir, Hirva Mamdani, Heidi Gillenwater, Yeonhee Kim, David R Spigel, Usama Gergis, Hemant S Murthy, Lubna N Chaudhary, Sarah Fitzsimmons, Bishwa J Ganguly, Hajime Hiraragi, Helle Jensen, Mary C Lessig
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items